PRF Technologies Clears FDA Hurdle for OcuRing-K Phase II Trial
Event summary
- PRF Technologies received FDA clearance for its IND application for OcuRing™-K, advancing to Phase II trials.
- The trial will evaluate the bio-erodible intraocular ring's efficacy in post-cataract surgery pain and inflammation management.
- Patient enrollment is expected to begin in the second half of 2026 across multiple U.S. centers.
- OcuRing™-K aims to replace traditional eye-drop regimens with a single intraoperative application.
The big picture
PRF Technologies' FDA clearance for OcuRing-K Phase II trials marks a strategic step in addressing the unmet need for consistent post-surgical pain management. The shift from topical eye drops to sustained-release intraocular delivery aligns with broader industry trends toward minimizing patient burden and improving adherence. Success here could position PRF as a key player in ophthalmic drug-delivery innovation, leveraging its majority-owned LayerBio subsidiary to expand into additional therapeutic areas.
What we're watching
- Clinical Efficacy
- Whether OcuRing-K can demonstrate superior pain reduction and inflammation control compared to existing eye-drop regimens.
- Market Differentiation
- The pace at which PRF can position OcuRing-K as a standard-of-care alternative in cataract surgery recovery.
- Platform Expansion
- How LayerBio's broader ophthalmic platform may support additional drug-delivery applications beyond NSAIDs.
Related topics